Literature DB >> 19360443

Measurement of the sensitivity of different commercial assays in the diagnosis of CMV infection in pregnancy.

M Gentile1, C Galli, P Pagnotti, P Di Marco, S Tzantzoglou, F Bellomi, M L Ferreri, C Selvaggi, G Antonelli.   

Abstract

To evaluate the performance of different commercial assays for the detection of recent cytomegalovirus (CMV) in pregnancy, the sensitivity and specificity of assays for CMV-specific IgM antibodies were compared. Routine specimens from pregnant women were screened for CMV IgM using the Abbott AxSYM assay. Sera that were reactive according to AxSYM were further tested for IgM by other commercial assays. In selected IgM positive samples a CMV IgG avidity assay (Radim) and virus isolation from urine (shell vial) were also performed. The positivity rate for IgM anti-CMV by AxSYM was relatively high (140 out of 492, combining reactive and grayzone results). Only 26 of the 140 samples were positive for IgM according to Radim. The IgG avidity was low in 16 of the 43 samples tested, and the Radim and DiaSorin IgM assays were negative in 5 of them; 2 of the latter cases were also positive for viral isolation according to a shell vial method. There are differences in the sensitivity of the commercially available tests for CMV antibodies. CMV screening in pregnancy is performed as a first step by immunoassays and the choice of highly sensitive IgM test associated with further serological and virological methods could help to identify early primary infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19360443     DOI: 10.1007/s10096-009-0738-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  30 in total

1.  Early identification of human cytomegalovirus strains by the shell vial assay is prevented by a novel amino acid substitution in UL123 IE1 gene product.

Authors:  G Gerna; F Baldanti; E Percivalle; M Zavattoni; G Campanini; M G Revello
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

2.  Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus.

Authors:  A J Dahle; K B Fowler; J D Wright; S B Boppana; W J Britt; R F Pass
Journal:  J Am Acad Audiol       Date:  2000-05       Impact factor: 1.664

3.  Randomised controlled trial of genetic amniocentesis in 4606 low-risk women.

Authors:  A Tabor; J Philip; M Madsen; J Bang; E B Obel; B Nørgaard-Pedersen
Journal:  Lancet       Date:  1986-06-07       Impact factor: 79.321

4.  Different profiles of cytomegalovirus RNA transcripts and anti-cytomegalovirus IgM antibodies in renal transplant recipients.

Authors:  V J Goossens; C Vink; W Mullers; J M Middeldorp; C A Bruggeman
Journal:  J Clin Virol       Date:  2001-12       Impact factor: 3.168

5.  Evaluation of the Abbott AxSYM cytomegalovirus (CMV) immunoglobulin M (IgM) assay in conjunction with other CMV IgM tests and a CMV IgG avidity assay.

Authors:  T Lazzarotto; C Galli; R Pulvirenti; R Rescaldani; R Vezzo; A La Gioia; C Martinelli; S La Rocca; G Agresti; L Grillner; M Nordin; M van Ranst; B Combs; G T Maine; M P Landini
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

6.  Passive immunization during pregnancy for congenital cytomegalovirus infection.

Authors:  Giovanni Nigro; Stuart P Adler; Renato La Torre; Al M Best
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

7.  Prenatal diagnosis of human cytomegalovirus by culture and polymerase chain reaction: 98 pregnancies leading to congenital infection.

Authors:  M Bodéus; C Hubinont; P Bernard; A Bouckaert; K Thomas; P Goubau
Journal:  Prenat Diagn       Date:  1999-04       Impact factor: 3.050

8.  IgM antibody detection of ppUL80A and ppUL32 by immunoblotting: an early parameter for recurrent cytomegalovirus infection in renal transplant recipients.

Authors:  Y J Kraat; F S Stals; M H Christiaans; T Lazzarotto; M P Landini; C A Bruggeman
Journal:  J Med Virol       Date:  1996-03       Impact factor: 2.327

9.  Multicity Italian study of congenital cytomegalovirus infection.

Authors:  Maria Barbi; Sandro Binda; Simona Caroppo; Agata Calvario; Cinzia Germinario; Anna Bozzi; Maria Luisa Tanzi; Licia Veronesi; Ida Mura; Andrea Piana; Giuliana Solinas; Lorenza Pugni; Giulio Bevílaqua; Fabio Mosca
Journal:  Pediatr Infect Dis J       Date:  2006-02       Impact factor: 2.129

10.  Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay.

Authors:  M P Landini; T Lazzarotto; G T Maine; A Ripalti; R Flanders
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

View more
  5 in total

Review 1.  Systematic review of the birth prevalence of congenital cytomegalovirus infection in developing countries.

Authors:  Tatiana M Lanzieri; Sheila C Dollard; Stephanie R Bialek; Scott D Grosse
Journal:  Int J Infect Dis       Date:  2014-03-12       Impact factor: 3.623

2.  Prevention of maternal cytomegalovirus infection: current status and future prospects.

Authors:  Jessica L Nyholm; Mark R Schleiss
Journal:  Int J Womens Health       Date:  2010-08-09

Review 3.  Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy.

Authors:  Harry E Prince; Mary Lapé-Nixon
Journal:  Clin Vaccine Immunol       Date:  2014-08-27

Review 4.  Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays.

Authors:  Bettie Voordouw; Barry Rockx; Thomas Jaenisch; Pieter Fraaij; Philippe Mayaud; Ann Vossen; Marion Koopmans
Journal:  Clin Microbiol Rev       Date:  2019-12-11       Impact factor: 26.132

5.  Clinical evaluation of new automated cytomegalovirus IgM and IgG assays for the Elecsys(®) analyser platform.

Authors:  M G Revello; C Vauloup-Fellous; L Grangeot-Keros; J van Helden; Y Dickstein; I Lipkin; A Mühlbacher; T Lazzarotto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-01       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.